Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab

S. Rossi, C. Motta, V. Studer, V. De Chiara, F. Barbieri, F. Monteleone, A. Fornasiero, G. Coarelli, G. Bernardi, G. Cutter, O. Stüve, M. Salvetti, D. Centonze

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background and purpose: Multiple sclerosis (MS) patients discontinuing natalizumab are at risk of rebound of disease activity. Methods: In the present multi-center, open-label, non-randomized, prospective, pilot study, we tested whether treatment with glatiramer acetate (GA) is safe and effective after natalizumab in MS patients. The study was performed at academic tertiary medical centers. Forty active relapsing-remitting MS patients who never failed GA therapy and who discontinued natalizumab after 12-18 months of therapy were enrolled. GA was initiated 4 weeks after the last dose of natalizumab. Results: 62.5% of patients were relapse-free 12 months after GA initiation. Annualized relapse rate and time to relapse were significantly lower than before natalizumab. Notably, the frequency of relapses was significantly lower amongst those patients who had experienced ≤2 relapses the year before initiation of natalizumab therapy, compared with patients who had had three or more relapses. No evidence of rebound was observed in magnetic resonance imaging scans. Furthermore, Expanded Disability Status Scale and Multiple Sclerosis Functional Composite were stable in our patients, again suggesting that 12 months of post-natalizumab-GA therapy is not associated with clinical deterioration. Conclusions: Following discontinuation of natalizumab, 12 months of therapy with GA is safe and well tolerated in MS patients. GA can reduce the risk of early reactivation/rebound of disease activity in this setting.

Original languageEnglish (US)
Pages (from-to)87-94
Number of pages8
JournalEuropean Journal of Neurology
Volume20
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Multiple Sclerosis
Recurrence
Therapeutics
Relapsing-Remitting Multiple Sclerosis
Glatiramer Acetate
Natalizumab
Magnetic Resonance Imaging
Prospective Studies

Keywords

  • Immunomodulation
  • JCV
  • PML
  • Rebound
  • Relapse

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Rossi, S., Motta, C., Studer, V., De Chiara, V., Barbieri, F., Monteleone, F., ... Centonze, D. (2013). Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. European Journal of Neurology, 20(1), 87-94. https://doi.org/10.1111/j.1468-1331.2012.03794.x

Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. / Rossi, S.; Motta, C.; Studer, V.; De Chiara, V.; Barbieri, F.; Monteleone, F.; Fornasiero, A.; Coarelli, G.; Bernardi, G.; Cutter, G.; Stüve, O.; Salvetti, M.; Centonze, D.

In: European Journal of Neurology, Vol. 20, No. 1, 01.2013, p. 87-94.

Research output: Contribution to journalArticle

Rossi, S, Motta, C, Studer, V, De Chiara, V, Barbieri, F, Monteleone, F, Fornasiero, A, Coarelli, G, Bernardi, G, Cutter, G, Stüve, O, Salvetti, M & Centonze, D 2013, 'Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab', European Journal of Neurology, vol. 20, no. 1, pp. 87-94. https://doi.org/10.1111/j.1468-1331.2012.03794.x
Rossi, S. ; Motta, C. ; Studer, V. ; De Chiara, V. ; Barbieri, F. ; Monteleone, F. ; Fornasiero, A. ; Coarelli, G. ; Bernardi, G. ; Cutter, G. ; Stüve, O. ; Salvetti, M. ; Centonze, D. / Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. In: European Journal of Neurology. 2013 ; Vol. 20, No. 1. pp. 87-94.
@article{1f4a68dba155494c9c6d2d7bc24c551c,
title = "Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab",
abstract = "Background and purpose: Multiple sclerosis (MS) patients discontinuing natalizumab are at risk of rebound of disease activity. Methods: In the present multi-center, open-label, non-randomized, prospective, pilot study, we tested whether treatment with glatiramer acetate (GA) is safe and effective after natalizumab in MS patients. The study was performed at academic tertiary medical centers. Forty active relapsing-remitting MS patients who never failed GA therapy and who discontinued natalizumab after 12-18 months of therapy were enrolled. GA was initiated 4 weeks after the last dose of natalizumab. Results: 62.5{\%} of patients were relapse-free 12 months after GA initiation. Annualized relapse rate and time to relapse were significantly lower than before natalizumab. Notably, the frequency of relapses was significantly lower amongst those patients who had experienced ≤2 relapses the year before initiation of natalizumab therapy, compared with patients who had had three or more relapses. No evidence of rebound was observed in magnetic resonance imaging scans. Furthermore, Expanded Disability Status Scale and Multiple Sclerosis Functional Composite were stable in our patients, again suggesting that 12 months of post-natalizumab-GA therapy is not associated with clinical deterioration. Conclusions: Following discontinuation of natalizumab, 12 months of therapy with GA is safe and well tolerated in MS patients. GA can reduce the risk of early reactivation/rebound of disease activity in this setting.",
keywords = "Immunomodulation, JCV, PML, Rebound, Relapse",
author = "S. Rossi and C. Motta and V. Studer and {De Chiara}, V. and F. Barbieri and F. Monteleone and A. Fornasiero and G. Coarelli and G. Bernardi and G. Cutter and O. St{\"u}ve and M. Salvetti and D. Centonze",
year = "2013",
month = "1",
doi = "10.1111/j.1468-1331.2012.03794.x",
language = "English (US)",
volume = "20",
pages = "87--94",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab

AU - Rossi, S.

AU - Motta, C.

AU - Studer, V.

AU - De Chiara, V.

AU - Barbieri, F.

AU - Monteleone, F.

AU - Fornasiero, A.

AU - Coarelli, G.

AU - Bernardi, G.

AU - Cutter, G.

AU - Stüve, O.

AU - Salvetti, M.

AU - Centonze, D.

PY - 2013/1

Y1 - 2013/1

N2 - Background and purpose: Multiple sclerosis (MS) patients discontinuing natalizumab are at risk of rebound of disease activity. Methods: In the present multi-center, open-label, non-randomized, prospective, pilot study, we tested whether treatment with glatiramer acetate (GA) is safe and effective after natalizumab in MS patients. The study was performed at academic tertiary medical centers. Forty active relapsing-remitting MS patients who never failed GA therapy and who discontinued natalizumab after 12-18 months of therapy were enrolled. GA was initiated 4 weeks after the last dose of natalizumab. Results: 62.5% of patients were relapse-free 12 months after GA initiation. Annualized relapse rate and time to relapse were significantly lower than before natalizumab. Notably, the frequency of relapses was significantly lower amongst those patients who had experienced ≤2 relapses the year before initiation of natalizumab therapy, compared with patients who had had three or more relapses. No evidence of rebound was observed in magnetic resonance imaging scans. Furthermore, Expanded Disability Status Scale and Multiple Sclerosis Functional Composite were stable in our patients, again suggesting that 12 months of post-natalizumab-GA therapy is not associated with clinical deterioration. Conclusions: Following discontinuation of natalizumab, 12 months of therapy with GA is safe and well tolerated in MS patients. GA can reduce the risk of early reactivation/rebound of disease activity in this setting.

AB - Background and purpose: Multiple sclerosis (MS) patients discontinuing natalizumab are at risk of rebound of disease activity. Methods: In the present multi-center, open-label, non-randomized, prospective, pilot study, we tested whether treatment with glatiramer acetate (GA) is safe and effective after natalizumab in MS patients. The study was performed at academic tertiary medical centers. Forty active relapsing-remitting MS patients who never failed GA therapy and who discontinued natalizumab after 12-18 months of therapy were enrolled. GA was initiated 4 weeks after the last dose of natalizumab. Results: 62.5% of patients were relapse-free 12 months after GA initiation. Annualized relapse rate and time to relapse were significantly lower than before natalizumab. Notably, the frequency of relapses was significantly lower amongst those patients who had experienced ≤2 relapses the year before initiation of natalizumab therapy, compared with patients who had had three or more relapses. No evidence of rebound was observed in magnetic resonance imaging scans. Furthermore, Expanded Disability Status Scale and Multiple Sclerosis Functional Composite were stable in our patients, again suggesting that 12 months of post-natalizumab-GA therapy is not associated with clinical deterioration. Conclusions: Following discontinuation of natalizumab, 12 months of therapy with GA is safe and well tolerated in MS patients. GA can reduce the risk of early reactivation/rebound of disease activity in this setting.

KW - Immunomodulation

KW - JCV

KW - PML

KW - Rebound

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=84871652136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871652136&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1331.2012.03794.x

DO - 10.1111/j.1468-1331.2012.03794.x

M3 - Article

C2 - 22741530

AN - SCOPUS:84871652136

VL - 20

SP - 87

EP - 94

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 1

ER -